DBV Technologies S.A. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Filed May 4, 2023. Amounts below are U.S. dollars; financial statement amounts are rounded to millions unless stated otherwise.
Business context
DBV is a clinical-stage biopharmaceutical company developing Viaskin, a skin-patch platform for epicutaneous immunotherapy. Its lead program, Viaskin Peanut, is being studied in children with peanut allergy; the company had no sales in the quarter. Its operating income primarily reflects French research tax credits and collaboration-related income.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Sales | None | None |
| Operating income | $2.2 million | $2.5 million |
| Research and development expense | $16.0 million | $12.2 million |
| Total operating expenses | $23.4 million | $19.3 million |
| Loss from operations | $21.2 million | $16.8 million |
| Net loss | $20.6 million | $16.7 million |
| Basic and diluted loss per share | $0.22 | $0.30 |
| Cash and cash equivalents | $192.3 million at March 31, 2023 | $209.2 million at December 31, 2022 |
| Cash used in operating activities | $20.8 million | $1.5 million |
| Total liabilities | $53.8 million at March 31, 2023 | $52.1 million at December 31, 2022 |
There is no meaningful sales margin to assess because the company reported no sales. Financial income was $0.6 million, versus $0.2 million in Q1 2022. No bank debt was reported; liabilities include operating leases and contingencies. Total contingencies were $20.1 million, including a $19.1 million accrual related to estimated loss at completion of the Nestlé Health Science collaboration Phase 2 trial.
Material changes versus Q1 2022 and year-end 2022
- Net loss increased by $3.9 million, while operating expenses increased 21%, mainly reflecting higher clinical development spending.
- R&D expense rose by $3.8 million; the company attributed this chiefly to external clinical costs, including patient recruitment for the VITESSE Phase 3 trial.
- Operating income declined 14% to $2.2 million, primarily because of lower income recognized under the Nestlé collaboration; research tax credit income increased.
- Operating cash use was $20.8 million versus $1.5 million in Q1 2022. Management attributed the comparison mainly to a $20.9 million research-tax-credit reimbursement received in 2022.
- Cash declined $16.9 million from year-end; the cash-flow statement included a positive $3.9 million foreign-exchange effect.
- Weighted-average shares were 94.0 million versus 54.9 million in Q1 2022. The filing also lists 28.3 million prefunded warrants excluded from diluted EPS as anti-dilutive.
Outlook, management commentary, and key risks
- Management stated that cash and cash equivalents were expected to fund operations for at least the next 12 months based on current plans and assumptions. The company has incurred recurring losses and negative operating cash flows and expects to seek additional capital; financing availability and terms are uncertain.
- The company had an at-the-market program allowing sales of up to $100 million of ADSs, established in May 2022 and intended to remain effective through July 16, 2024, subject to its terms. The filing text does not provide a clear value for remaining capacity or quarter-to-date ATM sales.
- VITESSE, a Phase 3 trial of the modified Viaskin Peanut patch in children ages 4–7, screened its first patient in March 2023. The last-patient screening was anticipated in the first half of 2024 and topline results in the first half of 2025; these are forward-looking targets.
- In April 2023, after quarter-end, the FDA confirmed that the EPITOPE Phase 3 toddler study met its prespecified primary-endpoint success criteria and did not request another efficacy study. The FDA did require an additional safety study in children ages 1–3 to support a potential BLA; the study is also expected to collect patch-adhesion data and use updated instructions.
- The prior FDA partial clinical hold on VITESSE was lifted in December 2022 after protocol changes. Regulatory approval and timing remain uncertain. DBV withdrew its EU marketing application in 2021 and said it intends to resubmit when additional pivotal-trial data are available.
- Management reported no material legal proceedings, no material changes to the risk factors in its 2022 Form 10-K, and effective disclosure controls. The company cautions that clinical, regulatory, manufacturing, financing, and commercialization outcomes are uncertain.
Important facts for investors to verify
- VITESSE enrollment progress, trial execution, and whether anticipated screening and topline-result dates remain achievable.
- The design, timing, cost, and regulatory sufficiency of the FDA-requested toddler safety study and the path to a potential BLA.
- Cash burn and runway as clinical spending progresses, including the assumptions supporting management’s at-least-12-month liquidity statement.
- ATM program usage and remaining capacity, any additional financing needs, and potential dilution, including the substantial prefunded-warrant balance.
- Changes in the Nestlé collaboration accrual and other contingencies, and the status of any future EU filing strategy.